ENPP2 Human shRNA Plasmid Kit (Locus ID 5168)

CAT#: TL313207

ENPP2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided


Product Images

Specifications

Product Data
Locus ID 5168
Synonyms ATX; ATX-X; AUTOTAXIN; LysoPLD; NPP2; PD-IALPHA; PDNP2
Vector pGFP-C-shLenti
E. coli Selection Chloramphenicol (34 ug/ml)
Mammalian Cell Selection Puromycin
Format Lentiviral plasmids
Kit Components ENPP2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5168). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq NM_001040092, NM_001130863, NM_006209, NR_045555, NM_001330600, NM_001040092.1, NM_001040092.2, NM_006209.1, NM_006209.2, NM_006209.3, NM_006209.4, NM_001130863.1, NM_001130863.2, BC034961, BM694754, NM_001130863.3, NM_001040092.3, NM_006209.5
UniProt ID Q13822
Summary The protein encoded by this gene functions as both a phosphodiesterase, which cleaves phosphodiester bonds at the 5' end of oligonucleotides, and a phospholipase, which catalyzes production of lysophosphatidic acid (LPA) in extracellular fluids. LPA evokes growth factor-like responses including stimulation of cell proliferation and chemotaxis. This gene product stimulates the motility of tumor cells and has angiogenic properties, and its expression is upregulated in several kinds of carcinomas. The gene product is secreted and further processed to make the biologically active form. Several alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2008]
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@clinisciences.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@clinisciences.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

Documents